Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2015-05-06, 08:22:31 | version 1.38.0
26 Business performance Product revenue generated by the Biomaterials and Medical Products business group rose by 9.8 percent on 2013 to reach €97.9 million, a record result for the seventh year in succession. Since Heraeus Medical was founded in 2004, its revenue has grown by an average of around 10 percent each year. The business group’s revenue growth was well in excess of the 2014 industry average of 3 percent 3) . This growth was driven by upward movements in the established markets in Europe and North America and by better-than-expected sales of the revision cement that was introduced last year to treat trauma-related bone defects, including in the Biomaterials and Medical Products business group Heraeus Medical presence of multi-resistant germs. Enhancement of the dis- tributor structure in China and a range of product launches in various countries also contributed to revenue growth. In the coming years, an increase is expected in the number of implant-related infections resulting from joint replace- ment surgery. This trend is being driven by the growing use of implants as a result of demographic change and by rising incidences of multiple morbidities in ageing patients. Products used in anti-infective therapy and in support thera pies for implant-related infections will therefore become increasingly important. Heraeus Medical is responding to this trend by expanding its product portfolio and by offering products with various antibiotic additives and antibiotic combinations for a range of indications. The Biomaterials and Medical Products business group (Heraeus Medical) concentrates on medical products for orthopedic surgery as well as traumatology and biosurgery. It develops, produces, and globally markets biomaterials used in bone and joint surgery and to stabilize spinal fractures. Core product PALACOS® , the gold standard among bone cements, has proved its worth in clinical use for decades. New to the implant fixation portfolio is a cleaning system, a jet lavage, that cleans the bones prior to the application of the cement, and a system for mixing and applying the bone cements themselves. Product revenue € million 2014 2013 2012 2011 2010 89.2 97.9 80.8 74.7 67.0 3) 2013 Orthoworld Annual Report, Exhibit 3, p. 3